Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.
It was the newly-empowered Democrats’ turn to take on pharma drug pricing in the US this week, as senator Bernie Sanders and representative Elijah Cummings introduced legislation to curb fu
